REGENERX BIOPHARMACEUTICALS, INC. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/53d6b4eb-76e7-45c6-81ad-369a17372cfb/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2022 | $76.8k | 2022-01-01 – 2022-12-31 | evidence 0001410578-23-000628 |
| FY 2021 | $76.8k | 2021-01-01 – 2021-12-31 | evidence 0001104659-22-040167 |
| FY 2020 | $76.8k | 2020-01-01 – 2020-12-31 | evidence 0001104659-21-030728 |
| FY 2019 | $76.8k | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-036901 |
| FY 2018 | $69.7k | 2018-01-01 – 2018-12-31 | evidence 0001144204-19-016982 |
| FY 2017 | $56.7k | 2017-01-01 – 2017-12-31 | evidence 0001144204-18-017995 |
| FY 2016 | $93.3k | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-017360 |
| FY 2015 | $60.6k | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-093682 |
| FY 2014 | $0 | 2014-01-01 – 2014-12-31 | evidence 0001144204-16-093682 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
REGENERX BIOPHARMACEUTICALS, INC. — all facts · Net Income · Operating Income